Elscint has shown progressin increasing its position in the U.S. market. Historically, theIsraeli-based medical imaging vendor has been stronger in Europethan in the U.S. With scanner sales sagging in both markets, Elscintviews boosting its U.S. share as
Elscint has shown progressin increasing its position in the U.S. market. Historically, theIsraeli-based medical imaging vendor has been stronger in Europethan in the U.S. With scanner sales sagging in both markets, Elscintviews boosting its U.S. share as an opportunity to maintain itsrevenues.
The vendor saw revenue rise 8% in fiscal 1993 (end-December)to $238 million from $221 million in 1992. However, U.S. saleswere up nearly 50% for the year. Net income rose 7% -- not countingthe $4.8 million positive effect of a change in accounting methods-- from $20 million in 1992 to $21.5 million last year.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
2 Commerce Drive
Cranbury, NJ 08512